SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 13.63 |
| Enterprise Value ($M) | -10.11 |
| Book Value ($M) | 22.10 |
| Book Value / Share | 3.32 |
| Price / Book | 0.62 |
| NCAV ($M) | 22.10 |
| NCAV / Share | 3.32 |
| Price / NCAV | 0.62 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.73 |
| Return on Assets (ROA) | -0.54 |
| Return on Equity (ROE) | -0.75 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.66 |
| Current Ratio | 10.66 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 24.39 |
| Assets | 24.39 |
| Liabilities | 2.29 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 96 | 4,740 | 2.03 | |
| 52 | 8,509 | 0.61 | |
| 583 | 5,194 | 11.22 | |
| 63 | 327 | 19.27 | |
| 3 | 1,245 | 0.24 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| LTRN – Lantern Pharma Inc. | MBIO – Mustang Bio, Inc. |
| MBRX – Moleculin Biotech, Inc. | MIRA – MIRA Pharmaceuticals, Inc. |
| MLTX – MoonLake Immunotherapeutics |